Back to Search
Start Over
Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.
- Source :
-
Oncotarget [Oncotarget] 2024 Jun 03; Vol. 15, pp. 355-359. Date of Electronic Publication: 2024 Jun 03. - Publication Year :
- 2024
-
Abstract
- Ibrutinib was the first Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL). While producing durable responses and prolonging survival, roughly 20-25% of patients experience dose limiting side effects, mostly consisting of cardiovascular toxicities like severe hypertension and atrial fibrillation. While clinical predictors of BTK inhibitor-related cardiotoxicity have been proposed and may aid in risk stratification, there is no routine risk model used in clinical practice today to identify patients at highest risk. A recent study investigating genetic predictors of ibrutinib-related cardiotoxicity found that single nucleotide polymorphisms in KCNQ1 and GATA4 were significantly associated with cardiotoxic events. If replicated in larger studies, these biomarkers may improve risk stratification in combination with clinical factors. A clinicogenomic risk model may aid in identifying patients at highest risk of developing BTK inhibitor-related cardiotoxicity in which further risk mitigation strategies may be explored.
- Subjects :
- Humans
Adenine analogs & derivatives
Adenine adverse effects
Risk Assessment
Pyrimidines adverse effects
Pyrazoles adverse effects
Biomarkers
Polymorphism, Single Nucleotide
KCNQ1 Potassium Channel genetics
Tyrosine Kinase Inhibitors
Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors
Agammaglobulinaemia Tyrosine Kinase genetics
Protein Kinase Inhibitors adverse effects
Cardiotoxicity etiology
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Piperidines adverse effects
Piperidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1949-2553
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Oncotarget
- Publication Type :
- Academic Journal
- Accession number :
- 38829647
- Full Text :
- https://doi.org/10.18632/oncotarget.28589